In a recent trial, levosimendan therapy failed to ameliorate sepsis-induced organ dysfunction or improve the survival of patients with septic shock. The failure of levosimendan and many other potential therapies for sepsis, together with the findings of histopathologic studies, raise questions regarding the pathophysiologic basis of the disorder.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
microRNA-193-3p attenuates myocardial injury of mice with sepsis via STAT3/HMGB1 axis
Journal of Translational Medicine Open Access 09 September 2021
-
LncRNA THRIL is upregulated in sepsis and sponges miR-19a to upregulate TNF-α in human bronchial epithelial cells
Journal of Inflammation Open Access 10 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dellinger, R. P. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:2012. Crit. Care Med. 41, 580–637 (2012).
Gordon, A. C. et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1609409 (2016).
Hawiger, J., Veach, R. A. & Zienkiewicz, J. New paradigms in sepsis: from prevention to protection of failing microcirculation. J. Thromb. Haemost. 13, 1743–1756 (2015).
Marik, P. E. The demise of early goal-directed therapy for severe sepsis and septic shock. Acta Anaesthesiol. Scand. 59, 561–567 (2015).
Morelli, A. et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310, 1683–1691 (2013).
Mira, J. C. et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit. Care Med. http://dx.doi.org/10.1097/ccm.0000000000002074 (2016).
Hotchkiss, R. S. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230–1251 (1999).
Takasu, O. et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am. J. Respir. Crit. Care Med. 187, 509–517 (2013).
Hotchkiss, R. S. & Moldawer, L. L. Parallels between cancer and infectious disease. N. Engl. J. Med. 371, 380–383 (2014).
Hotchkiss, R. S. & Opal, S. Immunotherapy for sepsis — a new approach against an ancient foe. N. Engl. J. Med. 363, 87–89 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.S.H. has received grant support from Medimmune, Bristol-Myers Squibb, and GlaxoSmithKline. T.J.G. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Graetz, T., Hotchkiss, R. Preventing organ failure in sepsis — the search continues. Nat Rev Nephrol 13, 5–6 (2017). https://doi.org/10.1038/nrneph.2016.171
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.171
This article is cited by
-
Utilizing big data from electronic health records in pediatric clinical care
Pediatric Research (2023)
-
microRNA-193-3p attenuates myocardial injury of mice with sepsis via STAT3/HMGB1 axis
Journal of Translational Medicine (2021)
-
LncRNA THRIL is upregulated in sepsis and sponges miR-19a to upregulate TNF-α in human bronchial epithelial cells
Journal of Inflammation (2020)
-
Managing organ dysfunction in critical care
Nature Reviews Nephrology (2017)